Introduction
There are problems regarding treatment approaches to Acinetobacter spp. in clinical practice because of their increasing resistance rates (1) . The resistance rate to the antibacterial agents differs between hospitals. This is why it is important to know the resistance trends of specific microorganisms causing problems for each hospital, so as to apply an appropriate treatment protocol. The aim of this study was to investigate nosocomial infections caused by A. baumannii in the intensive care units (ICUs) of Atatürk Training and Research Hospital and determine resistance rates by years.
Materials and methods
Infections due to A. baumannii that were diagnosed and treated in ICUs of Atatürk Training and Research Hospital were evaluated. X-ray in the presence of purulent tracheal secretions, supported by a growth of ≥10 5 CFU/mL bacteria in a quantitative culture of deep endotracheal aspirate. For nonventilated patients, the diagnosis of nosocomial pneumonia was considered when they had a compatible chest X-ray and purulent sputum, with Gram staining and sputum culture documenting the presence of a pathogenic microorganism. Bacteremia was diagnosed by these criteria: a recognized pathogen cultured from 1 or more blood cultures or fever (>38 °C), chills or hypotension, and the presence of at least 1 of the following: 1) common skin contaminants (diphtheroids, Bacillus spp., Propionibacterium spp., coagulase-negative Staphylococci, or Micrococcus spp.) cultured from 2 or more blood cultures drawn on separate occasions, and 2) common skin contaminants cultured in at least 1 blood culture from patients with central line catheters already undergoing antibiotic therapy. A urinary tract infection in a patient with an indwelling bladder catheter was diagnosed with the detection of pyuria (≥10 leukocytes/mm 3 ), growth of ≥10 5 CFU/mL bacteria (no more than 2 species) in urine culture, and clinical signs of infection (fever of ≥38 °C, leucocytosis, abnormal macroscopic appearance of urine, presence of urinary nitrites). Other site-specific infections were diagnosed based on the CDC criteria (2-5).
Microbiological identification and resistance determination
The strains of A. baumannii were identified and defined through use of Gram staining, oxidase test, and half-automatized BBL crystal kits according to the manufacturer's recommendations. Consecutive isolates in the same nosocomial infection episode were excluded from the study. Susceptibility testing was done using the Kirby-Bauer disk diffusion method according to Clinical Laboratory Standards Institute (CLSI) criteria (6).
Ampicillin Colistin susceptibility was performed with 10-µg colistin disks and isolates were considered susceptible to colistin if inhibition zones were ≥11 mm, as recommended by the CLSI for Pseudomonas aeruginosa. E-test or microdilution was performed as a confirmatory test for strains found resistant to colistin in the disk diffusion method. For tigecycline susceptibility, the FDA clinical minimum inhibitory concentration (MIC) breakpoints for Enterobacteriaceae (<2 mg/L, sensitive) were used. Cefoperazone/sulbactam susceptibility was analyzed via the disk diffusion test; CLSI criteria for susceptibility breakpoints for cefoperazone were used (6). The susceptibility rates of antibiotics were compared by year from 2008 to 2011.
Statistical analysis
Statistical analysis was performed with SPSS 11.5 (SPSS Inc., Chicago, IL, USA). The statistical significance was set as P < 0.05. Pearson's chi-square test was used to compare categorical variables.
Results
A total of 252 infection episodes due to A. baumannii were detected in 229 patients during the study period. Nineteen patients had 2 or more infection episodes. Most infection episodes were diagnosed in the reanimation ICU. This unit was followed by the neurosurgery-neurology ICU (Table  1) . When data were evaluated according to infection site, the ranking and distribution of Acinetobacter infections were as follows: ventilator-associated pneumonia (76.7%), catheter-related blood-stream infection (12.3%), and primary bacteremia (7.9%) ( Table 2 ). The resistance rate to imipenem increased to 98.4% in 2011 from 54.0% in 2008. The resistance rate of meropenem increased, as 
Discussion
Acinetobacter species have not been accepted as etiologic agents because of their low pathogenicity, even though they were isolated from clinical specimens half a century ago. However, currently this microorganism is responsible for nosocomial infections causing high morbidity and mortality rates, especially in ICUs. Recently, a high resistance rate to carbapenems has led to the increased use of polymyxins for treatment purposes. Unfortunately, resistance to polymyxin, which is often the only treatment option, is now being reported (7). Acinetobacter multiresistance is identified in 2 ways: either as carbapenem resistance or as resistance to 3 different classes of antibiotics. Carbapenem resistance mechanisms in Acinetobacter species can be listed as follows: metallo-beta-lactamases, similar to IMP, VIM, SIM, NDM-1, and NDM-2; oxacillinases, such as OXA-23, OXA-24, OXA-58, and OXA-51; decrease in PBP-2 expression due to changes in PBP; and changes in outer membrane proteins. The most worrying resistance mechanism is that of carbapenemase activity among betalactamases, because resistance determinants can be found through plasma or transposons and transferred laterally among bacteria (7).
Imipenem resistance was found to be 54% in 2008 and 98.9% in 2011 in our study. Meropenem resistance was detected as 78.5% and 98.5% in the same years. The difference in the resistance rates was found to be statistically significant for each carbapenem (Table 3) (13, 14, 16) . In another study performed at the Konya Education and Research Hospital, imipenem resistance was reported as 50% in 2008 and 83% in 2010 (17) . The imipenem resistance rate was found as 91.7% in the Acinetobacter isolates that were responsible for ventilatorassociated pneumonia between January 2009 and January and March 2011 by Tasbakan et al. (18) . When compared to other studies, the lower resistance rates in our hospital in 2008 may be related to the fact that patients have only been admitted to ICUs since the beginning of 2007. However, it is difficult to compare these rates without "defined daily dosage" data for each hospital.
In the cephalosporin group, the resistance rate of cefoperazone/sulbactam was found to be higher than the previous rates (45.7% in 2008 versus 90.3% in 2011). The difference was statistically significant. In a study performed in Turkey by Dizbay et al., the cefoperazone/ sulbactam resistance rate was detected as 77% in the 2008 isolates (13) . The resistance rate of cefoperazone/ sulbactam was reported as 63.9% for Acinetobacter spp. (18, 19) . Sulbactam seems to be a potential alternative agent in the treatment of multidrug-resistant Acinetobacter infections due to the intrinsic activity against these isolates (20) (21) (22) . However, there is no well-controlled clinical study proving this effect in the published English literature. It is not possible to comment with any certainty about cefoperazone/ sulbactam resistance because no defined criteria have been determined by the CLSI for these agents. The resistance rate for sulbactam could not be evaluated because sulbactam was not available as a single agent in Turkey during the study period.
The resistance rates of cefepime and ampicillin/ sulbactam decreased to 96.8% and 93.5% in 2011 from 97.6% and 95.7% in 2008. We thought that this may be related to infrequent usage of these antibiotics in the treatment of ICU-acquired infections due to high resistance rates.
When we evaluated aminoglycosides, there was no significant difference in the resistance rates for amikacin and gentamicin by year, but the resistance rates of tobramycin and netilmicin rose. However, this increase was not found to be statistically significant. The resistance rate of netilmicin was reported as 24.9% in a study performed by Özdemir et al. (15) . Tasbakan et al. reported a 54.2% netilmicin resistance rate in the isolates that were the responsible agents of ventilator-associated pneumonia between 2009 and 2011 (18) . The resistance rate was reported as 71% in another study performed by Mansur et al. (14) .
The resistance rates to amikacin and gentamicin decreased in 2011 in comparison with 2008. Netilmicin was preferred over other aminoglycosides due to the increasing resistance rates of Acinetobacter infections. This may explain the decreasing resistance rates to amikacin and gentamicin and the increasing resistance to netilmicin. The resistance rate to trimethoprim/ sulfamethoxazole decreased to 72% in 2011 from 91.7% in 2008. The difference in the resistance rates was statistically significant (P < 0.05). The reason for this difference may be related to the low usage rate of trimethoprim/ sulfamethoxazole to treat ICU-acquired infections. Trimethoprim/sulfamethoxazole could be an alternative, or additional, agent in the treatment of pan-drug-resistant A. baumannii infections.
The other alternative antimicrobial agent in the treatment of infections due to multidrug-resistant Acinetobacter spp. is tigecycline. Tigecycline has been used since 2007 and resistance to this antibiotic developed rapidly in our hospital (Table 3) . We think that this situation may be due to the intensive usage of tigecycline in the treatment of nonapproved indications, such as nosocomial pneumonia, because of the limited availability of colistin until 2010 (23) . The tigecycline resistance rates were reported as 0.9% and 0% in the studies performed by Özdemir et al. and Mansur et al. in 2008 (14,15 (17) . Similar rates were found in our study for the same years.
There is not a high resistance to colistin in Turkey, and there is only one published case of colistin-resistant A. baumannii from Turkey (24) . Because of this, colistin susceptibility was performed via disk diffusion method and E-test as a confirmatory method, although it was not recommended by the CLSI. A total of 4 isolates were found to be colistin-resistant, and these were confirmed by E-test. The pathogenesis of emerging resistance in Acinetobacter is not well identified. In a recent study it was shown that loss of lipopolysaccharide (LPS) production can cause this resistance without previous colistin usage (25) . In another report, mechanisms were defined as mutations in 2 genes that constitute a 2-component system (PmrAB) involved in the modification of lipid A, the major constituent of LPS membranes, and mutations, deletions, or insertions in genes essential for the synthesis of lipid A (26) . Colistin resistance among Acinetobacter strains, especially in A. baumannii, is increasing. In different parts of the world such as France (26) , Argentina (27) , Spain (28), Kuwait (29) , and India (30), colistin-resistant Acinetobacter strains have been identified. There has been only one case of colistin-resistant Acinetobacter infection reported from Turkey (24).
In conclusion, there is a continuing problem regarding infections due to A. baumannii in our hospital and in Turkey. The increasing resistance rates to carbapenems and developing resistance to colistin are making the situation more serious and complicated.
